Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04497584 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC
A Phase 2 study of Advanced Squamous Non Small Cell Lung Cancer, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04497584 is a Phase 2 study of Advanced Squamous Non Small Cell Lung Cancer that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04497584, a Phase 2 study of Advanced Squamous Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the efficacy of combined afatinib and prednisone in previously treated advanced squamous NSCLC
Conditions Studied
Interventions
- DRUG Afatinib + Prednisone
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-08-04 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04497584
The ClinicalTrials.gov registry entry for NCT04497584 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Squamous Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Afatinib + Prednisone is the first listed.
NCT04497584 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04497584 about?
NCT04497584 is a clinical study titled "Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC". To determine the efficacy of combined afatinib and prednisone in previously treated advanced squamous NSCLC
What is the current status of trial NCT04497584?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-08-04. Estimated completion is 2027-09-01.
What conditions does trial NCT04497584 study?
This clinical trial studies the following conditions: Advanced Squamous Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT04497584?
The interventions under investigation include: Afatinib + Prednisone (DRUG).
Who is sponsoring clinical trial NCT04497584?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04497584 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.